MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Market by Therapeutics & Diagnostics and Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton Market Research has estimated the Middle East and Africa Alzheimer’s disease therapeutics and diagnostics market to show an upward trend in terms of revenue and grow rapidly with a CAGR of 8.24% in the forecasting years 2019-2027.

The countries that have been considered for analysis in the report on the Middle East and Africa Alzheimer’s disease therapeutics and diagnostics market are:

•           Saudi Arabia

•           Turkey

•           United Arab Emirates

•           South Africa

•           Rest of the Middle East & Africa

The number of initiatives taken, along with the investments for research by the government in this region to decline the prevalence of neurodegenerative or asymptomatic diseases is contributing to the growth of the Alzheimer’s disease therapeutics and diagnostics market. ­­­­

In recent times, awareness initiatives regarding Alzheimer’s have increased considerably. As a result, the governments in this region have started investing heavily in the R&D of drugs and diagnostic tests to treat Alzheimer’s disease. This will further bolster the demand for the Alzheimer’s disease therapeutics and diagnostics market over the forecast period. However, stringent government rules for the reimbursement process and inadequate financial conditions of the patients for the treatment are affecting the growth of Alzheimer’s disease therapeutics and diagnostics market. In addition, the scarcity of skilled professionals to deal with neurogenerative disorders such as AD presents a massive challenge for the growth of the Alzheimer’s disease therapeutics and diagnostics market.

AbbVie Inc. develops and offers drugs in therapeutic areas such as neuroscience, immunology, virology oncology, and general medicine. In neuroscience, it is focusing on its advancing its research across several neurogenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. In 2016, the company generated a revenue of $25.6 billion, which is attributable to its strong workforce of over 29,000 employees including researchers, scientists, manufacturing specialists, communicators, and regulatory experts across the world in more than 70 countries.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT

Table of Content

1.    MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. KEY FINDINGS

2.8. INDUSTRY STRUCTURE

2.8.1. RESEARCH AND DEVELOPMENT

2.8.2. MANUFACTURING

2.8.3. RAW MATERIALS

2.8.4. END USER

2.8.5. WHOLESALERS

2.9. ALZHEIMER'S DISEASE ETIOLOGY

2.10. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.11. MARKET DRIVERS

2.11.1. GROWTH OF THE ALZHEIMER’S DISEASE

2.11.2. GROWING GERIATRIC POPULATION

2.11.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.12. MARKET RESTRAINTS

2.12.1. STRINGENT GOVERNMENT REGULATIONS

2.12.2. THE TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH

2.13. MARKET OPPORTUNITIES

2.13.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.13.2. R&D INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING

2.14. MARKET CHALLENGES

2.14.1. AWARENESS IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE

2.14.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE

3.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.3. PRODROMAL STAGE

3.1.4. THERAPEUTICS BY GENERIC AND BRANDED

3.1.4.1. BRANDED

3.1.4.2. GENERIC

3.2. DIAGNOSTIC TYPE

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – MIDDLE EAST AND AFRICA

4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2. COUNTRY ANALYSIS

4.2.1. SAUDI ARABIA

4.2.2. TURKEY

4.2.3. UNITED ARAB EMIRATES

4.2.4. SOUTH AFRICA

4.2.5. REST OF MIDDLE EAST & AFRICA

5.    COMPANY PROFILES

5.1. ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER

5.5. BIOGEN

5.6. COGNOPTIX

5.7. DIAGENIC ASA

5.8. ROCHE

5.9. GE HEALTHCARE

5.10. MERCK

5.11. JOHNSON & JOHNSON

5.12. PIRAMAL ENTERPRISES LTD.

5.13. SIEMENS HEALTHINEERS AG

5.14. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.    RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

            

List of table

TABLE 1        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 2        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($ MILLION)

TABLE 3        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($ MILLION)

TABLE 4        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 ($ MILLION)

TABLE 5        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

TABLE 6        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 7        MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

            

List of Figures

FIGURE 1      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 2      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 3      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)

FIGURE 4      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)

FIGURE 5      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)

FIGURE 6      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($ MILLION)

FIGURE 7      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)

FIGURE 8      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 ($ MILLION)

FIGURE 9      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 ($ MILLION)

FIGURE 10   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

FIGURE 11   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)

FIGURE 12   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 13   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)

FIGURE 14   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)

FIGURE 15   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 16   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)

FIGURE 17   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 18   SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 19   TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 20   UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 21   SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 22   REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;